Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 14/20 | 0.36 |
| ▸ | KDR | P35968 | 7/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | ABL1 | P00519 | 3/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | HCK | P08631 | 3/20 | 0.33 |
| ▸ | SRC | P12931 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | MTOR | P42345 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.33 |
| ▸ | PRKDC | P78527 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23239683 | 0.82 | ADORA1 (0.36) | ADORA2AADORA1NOS3NOS2 | |
| SCHEMBL25061711 | 0.78 | NOS2 (0.33) | ADORA2ANOS3NOS2 | |
| SCHEMBL23960225 | 0.74 | RET (0.52) | RETKDR | |
| SCHEMBL20334656 | 0.72 | ADORA2A (0.42) | RETKDRPIK3CDABL1EGFR | |
| SCHEMBL24492941 | 0.70 | NOS2 (0.45) | NOS3NOS2PI4KB | |
| SCHEMBL18212231 | 0.69 | ESR1 (0.41) | — | |
| SCHEMBL18212234 | 0.67 | PIK3CG (0.39) | RETKDRPIK3CDABL1EGFR | |
| SCHEMBL16375258 | 0.65 | RET (0.40) | RETKDR | |
| SCHEMBL31065824 | 0.65 | FFAR2 (0.42) | ADORA2AADORA1NOS3NOS2PI4KB | |
| SCHEMBL13708517 | 0.63 | MPO (0.42) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20220144843-A1 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-05-12 | — | — | US | disclosed |
| US-20210332057-A1 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230058545-A1 | HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES | HCK, LYN, BTK | RET 21/4885KDR 745/4885PIK3CD 668/4885 |
| US-20210332057-A1 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF | BTK, LCK, SYK | RET 1193/4885KDR 1518/4885PIK3CD 307/4885 |
| US-20220144843-A1 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOF | BTK, LCK, SYK | RET 1193/4885KDR 1518/4885PIK3CD 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.